BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15948940)

  • 1. Effect of the pediatric exclusivity provision on children's access to medicines.
    Grieve J; Tordoff J; Reith D; Norris P
    Br J Clin Pharmacol; 2005 Jun; 59(6):730-5. PubMed ID: 15948940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in availability of paediatric medicines in Australia between 1998 and 2002.
    Chui J; Tordoff J; Reith D
    Br J Clin Pharmacol; 2005 Jun; 59(6):736-42. PubMed ID: 15948941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to prescribing information for paediatric medicines in the USA: post-modernization.
    Young L; Lawes F; Tordoff J; Norris P; Reith D
    Br J Clin Pharmacol; 2009 Mar; 67(3):341-6. PubMed ID: 19220278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in accessibility to medicines for children in New Zealand: 1998-2002.
    Chui J; Tordoff J; Kennedy J; Reith D
    Br J Clin Pharmacol; 2004 Mar; 57(3):322-7. PubMed ID: 14998428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand.
    Ragupathy R; Aaltonen K; Tordoff J; Norris P; Reith D
    Pharmacoeconomics; 2012 Nov; 30(11):1051-65. PubMed ID: 22963187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002.
    Balakrishnan K; Tordoff J; Norris P; Reith D
    Br J Clin Pharmacol; 2007 Jan; 63(1):85-91. PubMed ID: 16869822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to children's medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007.
    Ragupathy R; Tordoff J; Norris P; Reith D
    Pharm World Sci; 2010 Jun; 32(3):386-93. PubMed ID: 20354788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The licensing of medicines in the UK.
    Drug Ther Bull; 2009 Apr; 47(4):45-8. PubMed ID: 19357299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Australian report on pediatric medication issues: is any magic happening in the 'Land of Oz' to save the therapeutic orphan?
    Beggs S
    Paediatr Drugs; 2009; 11(1):38-40. PubMed ID: 19127951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Improving drug licensing for children and adolescents : Position paper from the More Medicines for Minors Symposion 8 June 2015 in Bonn].
    Riedel C; Lehmann B; Broich K; Sudhop T
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Dec; 59(12):1587-1592. PubMed ID: 27778087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Access to new medicines in New Zealand compared to Australia.
    Wonder M; Milne R
    N Z Med J; 2011 Nov; 124(1346):12-28. PubMed ID: 22143849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Licensing and labelling of drugs in a paediatric oncology ward.
    van den Berg H; Tak N
    Br J Clin Pharmacol; 2011 Sep; 72(3):474-81. PubMed ID: 21453298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Brion F; Nunn AJ; Rieutord A
    Acta Paediatr; 2003 Apr; 92(4):486-90. PubMed ID: 12801118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extemporaneous (magistral) preparation of oral medicines for children in European hospitals.
    Conroy S
    Acta Paediatr; 2003 Apr; 92(4):408-10. PubMed ID: 12801103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the Therapeutic Goods Administration and the Medicine and Medical Devices Safety Authority in evaluating complementary and alternative medicines in Australia and New Zealand.
    Ghosh D; Skinner M; Ferguson LR
    Toxicology; 2006 Apr; 221(1):88-94. PubMed ID: 16481089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years.
    Ceci A; Felisi M; Baiardi P; Bonifazi F; Catapano M; Giaquinto C; Nicolosi A; Sturkenboom M; Neubert A; Wong I
    Eur J Clin Pharmacol; 2006 Nov; 62(11):947-52. PubMed ID: 17021892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The European paediatric legislation: benefits and perspectives.
    Rocchi F; Paolucci P; Ceci A; Rossi P
    Ital J Pediatr; 2010 Aug; 36():56. PubMed ID: 20716337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation.
    Lindell-Osuagwu L; Hakkarainen M; Sepponen K; Vainio K; Naaranlahti T; Kokki H
    J Clin Pharm Ther; 2014 Apr; 39(2):144-53. PubMed ID: 24329556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular medicines in children: the regulatory situation related to clinical research.
    Fortinguerra F; Clavenna A; Bonati M
    BMC Pediatr; 2012 Jan; 12():8. PubMed ID: 22264311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.